tbuckley/cabot-search huggingface dataset:
A smart MnO2-doped graphene oxide nanosheet for enhanced chemo-photodynamic combinatorial therapy via simultaneous oxygenation and glutathione depletion
Authors: Peng Liu, Xin Xie, Miao Liu, Shuo Hu, Jinsong Ding, Wenhu Zhou
Journal: Acta Pharmaceutica Sinica B (2020)

The combination of chemotherapy and photodynamic therapy provides a promising approach for enhanced tumor eradication by overcoming the limitations of each individual therapeutic modality. However, tumor is pathologically featured with extreme hypoxia together with the adaptable overexpression of anti-oxidants, such as glutathione (GSH), which greatly restricts the therapeutic efficiency. Here, a combinatorial strategy was designed to simultaneously relieve tumor hypoxia by self-oxygenation and reduce intracellular GSH level to sensitize chemo-photodynamic therapy. In our system, a novel multi-functional nanosystem based on MnO2-doped graphene oxide (GO) was developed to co-load cisplatin (CisPt) and a photosensitizer (Ce6). With MnO2 doping, the nanosystem was equipped with intelligent functionalities: (1) catalyzes the decomposition of H2O2 into oxygen to relieve the tumor hypoxia; (2) depletes GSH level in tumor cells, and (3) concomitantly generates Mn2+ to proceed Fenton-like reaction, all of which contribute to the enhanced anti-tumor efficacy. Meanwhile, the surface hyaluronic acid (HA) modification could facilitate the targeted delivery of the nanosystem into tumor cells, thereby resulting in amplified cellular toxicity, as well as tumor growth inhibition in nude mice model. This work sheds a new light on the development of intelligent nanosystems for synergistic combination therapy via regulating tumor microenvironment.
Author Correction: Defects in mtDNA replication challenge nuclear genome stability through nucleotide depletion and provide a unifying mechanism for mouse progerias
Authors: Riikka H. Hämäläinen, Juan C. Landoni, Kati J. Ahlqvist, Steffi Goffart, Sanna Ryytty, M. Obaidur Rahman, Virginia Brilhante, Katherine Icay, Sampsa Hautaniemi, Liya Wang, Marikki Laiho, Anu Suomalainen
Journal: Nature Metabolism (2020)
Pharmacokinetics of Hydroxyurea Therapy in African Children with Sickle Cell Anemia:Â Noharm Ancillary PK Study
Authors: Anu Marahatta, Min Dong, Robert Opoka, Kathryn E. McElhinney, Teresa S. Latham, Chandy C. John, Alexander A. Vinks, Russell E. Ware
Journal: Blood (2017)
What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?
Authors: Thomas Schön, Claudio Umberto Köser, Jim Werngren, Miguel Viveiros, Sophia Georghiou, Gunnar Kahlmeter, Christian Giske, Florian Maurer, Gerard Lina, John Turnidge, Jakko van Ingen, Mateja Jankovic, Delia Goletti, Daniela Maria Cirillo, Miguel Santin, Emmanuelle Cambau
Journal: Clinical Microbiology and Infection (2020)
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells
Authors: Imene Hamaidi, Lin Zhang, Nayoung Kim, Min-Hsuan Wang, Cristina Iclozan, Bin Fang, Min Liu, John M. Koomen, Anders E. Berglund, Sean J. Yoder, Jiqiang Yao, Robert W. Engelman, Ben C. Creelan, Jose R. Conejo-Garcia, Scott J. Antonia, James J. Mulé, Sungjune Kim
Journal: Cell Metabolism (2020)
IL-1 induces mitochondrial translocation of IRAK2 to suppress oxidative metabolism in adipocytes
Authors: Hao Zhou, Han Wang, Minjia Yu, Rebecca C. Schugar, Wen Qian, Fangqiang Tang, Weiwei Liu, Hui Yang, Ruth E. McDowell, Junjie Zhao, Ji Gao, Ashok Dongre, Julie A. Carman, Mei Yin, Judith A. Drazba, Robert Dent, Christopher Hine, Yeong-Renn Chen, Jonathan D. Smith, Paul L. Fox, J. Mark Brown, Xiaoxia Li
Journal: Nature Immunology (2020)
Association of Nursing Home Ratings on Health Inspections, Quality of Care, and Nurse Staffing With COVID-19 Cases
Authors: Jose F. Figueroa, Rishi K. Wadhera, Irene Papanicolas, Kristen Riley, Jie Zheng, E. John Orav, Ashish K. Jha
Journal: JAMA (2020)

"Abandoned" Nursing Homes Continue to Face Critical Supply and Staff Shortages as COVID-19 Toll Has Mounted
Breast Cancer Screening and Health Care Costs
Authors: Lars J. Grimm
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation
Authors: Adam Kosti, Patricia Rosa de Araujo, Wei-Qing Li, Gabriela D. A. Guardia, Jennifer Chiou, Caihong Yi, Debashish Ray, Fabiana Meliso, Yi-Ming Li, Talia Delambre, Mei Qiao, Suzanne S. Burns, Franziska K. Lorbeer, Fanny Georgi, Markus Flosbach, Sarah Klinnert, Anne Jenseit, Xiufen Lei, Carolina Romero Sandoval, Kevin Ha, Hong Zheng, Renu Pandey, Aleksandra Gruslova, Yogesh K. Gupta, Andrew Brenner, Erzsebet Kokovay, Timothy R. Hughes, Quaid D. Morris, Pedro A. F. Galante, Stefano Tiziani, Luiz O. F. Penalva
Journal: Genome biology (2020)

Abstract Background RNA-binding proteins (RBPs) function as master regulators of gene expression. Alterations in RBP expression and function are often observed in cancer and influence critical pathways implicated in tumor initiation and growth. Identification and characterization of oncogenic RBPs and their regulatory networks provide new opportunities for targeted therapy. Results We identify the RNA-binding protein SERBP1 as a novel regulator of glioblastoma (GBM) development. High SERBP1 expression is prevalent in GBMs and correlates with poor patient survival and poor response to chemo- and radiotherapy. SERBP1 knockdown causes delay in tumor growth and impacts cancer-relevant phenotypes in GBM and glioma stem cell lines. RNAcompete identifies a GC-rich region as SERBP1-binding motif; subsequent genomic and functional analyses establish SERBP1 regulation role in metabolic routes preferentially used by cancer cells. An important consequence of these functions is SERBP1 impact on methionine production. SERBP1 knockdown decreases methionine levels causing a subsequent reduction in histone methylation as shown for H3K27me3 and upregulation of genes associated with neurogenesis, neuronal differentiation, and function. Further analysis demonstrates that several of these genes are downregulated in GBM, potentially through epigenetic silencing as indicated by the presence of H3K27me3 sites. Conclusions SERBP1 is the first example of an RNA-binding protein functioning as a central regulator of cancer metabolism and indirect modulator of epigenetic regulation in GBM. By bridging these two processes, SERBP1 enhances glioma stem cell phenotypes and contributes to GBM poorly differentiated state.
A model-based approach for assessing bronchodilator responsiveness in children: The conventional cutoff revisited
Authors: Gianluca Sottile, Giuliana Ferrante, Giovanna Cilluffo, Salvatore Fasola, Velia Malizia, Vito M.R. Muggeo, Giovanni Viegi, Stefania La Grutta
Journal: Journal of Allergy and Clinical Immunology (2020)
Reply to: Proofreading deficiency in mitochondrial DNA polymerase does not affect total dNTP pools in mouse embryos
Authors: Riikka H. Hämäläinen, Juan C. Landoni, Kati J. Ahlqvist, Steffi Goffart, Sanna Ryytty, M. Obaidur Rahman, Virginia Brilhante, Katherine Icay, Sampsa Hautaniemi, Liya Wang, Marikki Laiho, Anu Suomalainen
Journal: Nature Metabolism (2020)
Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma
Authors: Charlotte Wilding, Farheen Mir, Indu Mitra, Bhupinder Sharma, Larissa Sena, Andrew Wotherspoon, David Cunningham, Ian Chau, Claire E. Dearden, Kabir Mohammed, Sunil Iyengar
Journal: Blood (2017)
Response to: ‘Correspondence on ‘<i>Festina lente</i>: hydroxychloroquine, COVID-19and the role of the rheumatologist’ by Graef<i>et al</i>’ by Lo<i>et al</i>
Authors: Ali Duarte-García, Elizabeth R Graef, Jean W Liew, Maximilian F Konig, Alfred Hyoungju Kim, Jeffrey A Sparks
Journal: Annals of the Rheumatic Diseases (2020)

We appreciate the interest of Lo et al in our opinion piece and thank them for the data presented in their letter.1 2 Several reports of QT prolongation and torsades de pointes in patients with COVID-19 receiving antimalarials have been published.3–5 These and other reports have indirectly raised questions regarding the arrhythmogenic potential of hydroxychloroquine (HCQ) when used to treat rheumatic disease.

Lo et al used the unique resource of the National Health Insurance Research Database of Taiwan. Through propensity scores, they matched patients who used HCQ and who did not use HCQ for the treatment of newly diagnosed rheumatoid arthritis (RA). Data about other disease-modifying antirheumatic drugs used by the patients was not reported. Therefore, it is unclear if the groups were similar in their RA disease severity, although they seemed similar related to comorbidities. The authors did not find differences in the cumulative risk of arrhythmia between the two groups after 1 year of follow-up. However, a prior meta-analysis on reported cardiotoxic events of antimalarials found that cardiac conduction abnormalities were the most common cardiac adverse events and were associated with higher cumulative doses (median cumulative HCQ dose of 1235 g, …
Consent during the covid-19 pandemic: surgeons need to think beyond the end of their scalpels now more than ever
Authors: Nigel S G Mercer
Journal: BMJ (2020)

The Federation of Surgical Specialty Associations (FSSA) published Developing Safe Surgical Service for the Covid Era on 22 May 2020.1 It was also presented in several webinars hosted by the Royal Colleges of …
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Authors: Sabra L. Klein, Andrew Pekosz, Han-Sol Park, Rebecca L. Ursin, Janna R. Shapiro, Sarah E. Benner, Kirsten Littlefield, Swetha Kumar, Harnish Mukesh Naik, Michael J. Betenbaugh, Ruchee Shrestha, Annie A. Wu, Robert M. Hughes, Imani Burgess, Patricio Caturegli, Oliver Laeyendecker, Thomas C. Quinn, David Sullivan, Shmuel Shoham, Andrew D. Redd, Evan M. Bloch, Arturo Casadevall, Aaron A.R. Tobian
Journal: Journal of Clinical Investigation (2020)

Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but there is a paucity of data identifying its therapeutic efficacy. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated using a severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) virus neutralization assay with Vero-E6-TMPRSS2 cells; a commercial IgG and IgA ELISA to detect the spike (S) protein S1 domain (EUROIMMUN); IgA, IgG, and IgM indirect ELISAs to detect the full-length S protein or S receptor–binding domain (S-RBD); and an IgG avidity assay. We used multiple linear regression and predictive models to assess the correlations between antibody responses and demographic and clinical characteristics. IgG titers were greater than either IgM or IgA titers for S1, full-length S, and S-RBD in the overall population. Of the 126 plasma samples, 101 (80%) had detectable neutralizing antibody (nAb) titers. Using nAb titers as the reference, the IgG ELISAs confirmed 95%–98% of the nAb-positive samples, but 20%–32% of the nAb-negative samples were still IgG ELISA positive. Male sex, older age, and hospitalization for COVID-19 were associated with increased antibody responses across the serological assays. There was substantial heterogeneity in the antibody response among potential convalescent plasma donors, but sex, age, and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody responses.
Technical Categories and Ethical Justifications: Why Cwik’s Approach is the Wrong Way Around for Categorizing Germ-Line Gene Editing
Authors: Anthony Wrigley, Ainsley J. Newson
Journal: The American Journal of Bioethics (2020)

Significant ethical differences imputed to the existing somatic/germline distinction indicate that technical categories play an important role in debates on gene editing. Yet, as Cwik rightly point...
Abstract 15538: Impact of Transitioning to High Sensitivity Troponin on the Evaluation of Chest Pain in Women
Authors: Sean Dikdan, Timothy Colangelo, Alexandra Ward, Joey Junarta, Brian Elliot, Andria Jones
Journal: Circulation (2019)

Introduction: Cardiac troponin is the gold standard for diagnosing myocardial injury. Advances in biochemical research have led to several cardiac troponin assays offering varying degrees of sensit...
Rapid genomic first- and second-line drug resistance prediction from clinical <i>Mycobacterium tuberculosis</i> specimens using Deeplex-MycTB
Authors: Silke Feuerriegel, Thomas A. Kohl, Christian Utpatel, Sönke Andres, Florian P. Maurer, Jan Heyckendorf, Agathe Jouet, Nelly Badalato, Lynda Foray, Rashidatu Fouad Kamara, Osman S. Conteh, Philip Supply, Stefan Niemann
Journal: European Respiratory Journal (2020)

<b>Targeted next generation sequencing using the Deeplex-MycTB assay can rapidly generate comprehensive drug resistance profiles from <i>Mycobacterium tuberculosis</i> complex cultures and directly from tuberculosis patient samples to guide personalised treatment</b>https://bit.ly/3dP1eIp
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
Authors: Mark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, William T Barry, Eric P Winer, Clifford Hudis, Deborah Toppmeyer, Lisa Anne Carey, Ann H Partridge, Jean-Yves Pierga, Tanja Fehm, José Vidal-Martínez, Dimitrios Mavroudis, Jose A Garcia-Saenz, Justin Stebbing, Paola Gazzaniga, Luis Manso, Rita Zamarchi, María Luisa Antelo, Leticia De Mattos-Arruda, Daniele Generali, Carlos Caldas, Elisabetta Munzone, Luc Dirix, Amy L Delson, Harold J Burstein, Misbah Qadir, Cynthia Ma, Janet H Scott, François-Clément Bidard, John W Park, Hope S Rugo
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P &amp;lt; .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.
Diagnostic workup including CD203c‐based basophil activation test in immediate hypersensitivity due to metronidazole and ornidazole and evaluation of cross‐reactivity in between
Authors: Şengül Beyaz, Nilgün Akdeniz, Abdullah Yılmaz, Semra Demir, Nida Öztop, Bahauddin Çolakoğlu, Suna Büyüköztürk, Günnur Deniz, Aslı Gelincik
Journal: Allergy (2020)

Little is known about the diagnostic approaches for immediate hypersensitivity reactions (IHRs) due to 5-nitroimidazole antibiotics. The aim was to evaluate the usefulness of in vivo tests and basophil activation test (BAT) for the diagnosis of IHRs due to metronidazole and ornidazole and to determine possible cross-reactivity in between.Forty-nine patients with a clear history of IHRs due to these drugs and 20 healthy subjects who were known to tolerate these drugs were included. Skin tests (STs) and single-blind placebo-controlled drug provocation tests (SBPCDPTs) were performed with both drugs whereas BAT was applied only with the culprit drug.The most and least common reaction types were urticaria/angioedema (34.7%) and anaphylaxis (14.3%), respectively. SBPCDPTs were positive in 15 out of 47 patients, and only 7 had positive STs. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of STs for metronidazole/ornidazole were 33.3%/16.6%, 94.2%/97.3%, 60%/50%, and 84.6%/88.1%, respectively. BAT was positive in 12 out of 15 patients and negative in 10 control subjects, giving a sensitivity rate of 71.4% (CI, 29.0%-96.3%) for metronidazole and 83.3% (CI, 35.8%-99.5%) for ornidazole. The optimal concentration of both drugs for BAT was determined as 5 mg/mL. No cross-reactivity among two drugs was observed according to in vivo tests.Our study showed that SBPCDPT and BAT are both useful diagnostic tools for IHRs due to 5-nitroimidazole antibiotics and can be used as supplementary to each other. No cross-reactivity between metronidazole and ornidazole in IHRs exists.
Continuous Nursing Support During Labor
Authors: John H. Kennell, Marshall H. Klaus
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
It Is Time to Consult the Children: A Mother Who Faced Mitochondrial Replacement and Her Son Consider the Limits of Genetic Modification
Authors: Susan M. Wolf, Jacob S. Borgida
Journal: The American Journal of Bioethics (2020)

Debate over the ethics of genetic modification of children born using In Vitro Fertilization (IVF) and other reproductive technologies has raged for years without including those most directly livi...
Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure
Authors: Asif K. Mustafa, Philip J. Alexander, Devang J. Joshi, Deborah R. Tabachnick, Chadrick A. Cross, Pat S. Pappas, Antone J. Tatooles
Journal: JAMA Surgery (2020)

Frederik M. Nielsen, MD; Thomas L. Klitgaard, MD, PhD; Martin Siegemund, MD; Jon H. Laake, MD, PhD; Katrin M. Thormar, MD, PhD; Jade M. Cole, RN, MSc; Søren R. Aagaard, MD, PhD; Anne-Marie G. Bunzel, RN; Stine R. Vestergaard, RN; Peter K. Langhoff, MD; Caroline H. Pedersen, MD; Josefine Ø. Hejlesen, MD; Salim Abdelhamid, MD; Anna Dietz, MD; Caroline E. Gebhard, MD; Nuria Zellweger, MD; Alexa Hollinger, MD; Lone M. Poulsen, MD; Sarah Weihe, MD; Nina C. Andersen-Ranberg, MD, PhD; Ulf G. Pedersen, MD, PhD; Ole Mathiesen, MD, PhD; Anne Sofie Andreasen, MD, PhD; Helene Brix, RN; Jonas J. Thomsen, MD; Christina H. Petersen, MD; Morten H. Bestle, MD, PhD; Sine Wichmann, MD; Martin S. Lund, MD, PhD; Karoline M. Mortensen, MD; Björn A. Brand, MD; Nicolai Haase, MD, PhD; Susanne A. Iversen, MD; Klaus V. Marcussen, MD; Anne C. Brøchner, MD, PhD; Morten Borup, MD; Thorbjørn Grøfte, MD, PhD; Thomas Hildebrandt, MD; Maj-Brit N. Kjær, RN, MSc; Janus Engstrøm, BSc; Theis Lange, MSc, PhD; Anders Perner, MD, PhD; Olav L. Schjørring, MD, PhD; Bodil S. Rasmussen, MD, PhD; HOT-COVID Trial Group; Anne S. B. Eriksen; Tina Jørgensen; Sanne Lauitzen; Lone Valbjørn; Ann B. Christensen; Niels Foldager; Henrik S. Sørensen; Trine Haberlandt; Annette Vennegaard; Tayyba N. Aslam; Helen Hill; Matthew P. Wise
DEVELOPMENT AND VALIDATION OF A ROBUST HIGH THROUGHPUT GENE EXPRESSION TEST (COLOPRINT) FOR RISK STRATIFICATION OF COLON CANCER PATIENTS
Authors: S. Bruin, P. Roepman, R. Salazar, G. Capella, V. Moreno, A. Glas, L. van 't Veer, R. Tollenaar
Journal: Annals of Oncology (2010)
Beirut’s battered hospitals struggle in aftermath of explosion
Authors: Owen Dyer
Journal: BMJ (2020)

Beirut, which was due to re-enter lockdown this week to tackle resurgent covid-19, must instead find shelter for nearly 300 000 newly homeless people, or about one resident in eight, after a blast of almost nuclear proportions devastated entire neighbourhoods of the city.

Three of Beirut’s hospitals were wrecked and closed by the blast, two others were damaged, and a warehouse that held stocks of medicines and most of the country’s vaccine supply was among the buildings flattened in the port district. More than three quarters of the grain in Lebanon, stored in port silos, was also lost.

A conflagration of fireworks nearby is believed to have detonated more than 2700 tonnes of ammonium nitrate stored in a port warehouse, producing a blast equivalent to between 200 and 1000 tonnes of TNT, roughly similar to the smallest …
Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma
Authors: C. Mahon, K. McHugh, N. Alband, D. Rampling, N. Sebire, E. Williamson, M. Glover, V.A. Kinsler
Journal: British Journal of Dermatology (2020)

Cutaneous infantile haemangioma (IH) occurs in 5-10% of neonates, with multiple IH (>1) in 30% of those1 . Expert opinion currently recommends routine liver ultrasound(USS) for five or more(5+ ) IH2,3 , and if hepatic haemangiomas(HH) are identified, to test thyroid function3 even if neonatal thyroid screening occurred. Supportive data from one cohort demonstrate associations between 5+ IH and HH1 , and between HH and adverse clinical outcomes (cardiac failure/hypothyroidism)4-6 .